Sotrovimab: A Review of Its Efficacy against SARS-CoV-2 Variants
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …
the most successful in having the longest temporal window of clinical use, showing a high …
An update on the anti-Spike monoclonal antibody pipeline for SARS-CoV-2
Abstract Background Anti-Spike monoclonal antibodies represent one of the most tolerable
prophylaxis and therapies for COVID-19 in frail and immunocompromised patients …
prophylaxis and therapies for COVID-19 in frail and immunocompromised patients …
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
A Gidari, S Sabbatini, S Bastianelli, S Pierucci, C Busti… - Viruses, 2024 - mdpi.com
Background: this study aims to evaluate the efficacy of tixagevimab/cilgavimab (Evusheld™)
against various SARS-CoV-2 variants, including newer Omicron sublineages, in an …
against various SARS-CoV-2 variants, including newer Omicron sublineages, in an …